Scribe secures $129M in a rare gene editing IPO

AI Summary

Scribe, a gene editing startup in the United States, secured $129 million through an IPO, marking the first gene editing IPO in over two years. The amount raised was significantly lower compared to other biotech companies that went public in 2026.

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotech companies that have gone public in 2026.